These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 10822902

  • 1. Time-dependence of survival predictions based on markers of HIV disease. Swiss HIV Cohort Study.
    Perneger TV, Abrahamowicz M, Bartlett G, Yerly S.
    J Investig Med; 2000 May; 48(3):207-12. PubMed ID: 10822902
    [Abstract] [Full Text] [Related]

  • 2. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 3. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M, Nogués Biau A, Falguera Sacrest M, Puig Ganau T, Lecha N, Rubio Rivas C.
    An Med Interna; 2000 Oct 01; 17(10):533-7. PubMed ID: 11109648
    [Abstract] [Full Text] [Related]

  • 4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 5. Early participation in an HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study.
    Battegay M, Wirz M, Steuerwald MH, Egger M.
    J Intern Med; 1998 Dec 15; 244(6):479-87. PubMed ID: 9893101
    [Abstract] [Full Text] [Related]

  • 6. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 Dec 15; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 7. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.
    AIDS; 2006 May 12; 20(8):1117-23. PubMed ID: 16691062
    [Abstract] [Full Text] [Related]

  • 8. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection.
    Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, Conant K, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Marder K, Epstein LG.
    Arch Neurol; 2007 Jan 12; 64(1):97-102. PubMed ID: 17210815
    [Abstract] [Full Text] [Related]

  • 9. Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults.
    Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, Gomo E, Butterworth AE, Pedersen BK, Ostrowski SR, Gerstoft J, Ullum H.
    AIDS; 2007 Nov 12; 21(17):2283-91. PubMed ID: 18090276
    [Abstract] [Full Text] [Related]

  • 10. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 12; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 11. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 12. Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model.
    Hendriks JC, Craib KJ, Veugelers PJ, van Druten HA, Coutinho RA, Schechter MT, van Griensven GJ.
    Int J Epidemiol; 2000 Jun 01; 29(3):565-72. PubMed ID: 10869332
    [Abstract] [Full Text] [Related]

  • 13. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM, ESLD-HIV Working Group Investigators.
    Liver Transpl; 2009 Sep 01; 15(9):1133-41. PubMed ID: 19718643
    [Abstract] [Full Text] [Related]

  • 14. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study.
    Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328
    [Abstract] [Full Text] [Related]

  • 15. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL, Henrick BM, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR.
    Antivir Ther; 2005 Oct 15; 10(7):849-53. PubMed ID: 16312181
    [Abstract] [Full Text] [Related]

  • 16. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study.
    AIDS; 2008 May 31; 22(9):1019-28. PubMed ID: 18520345
    [Abstract] [Full Text] [Related]

  • 17. [Survival and disease progression in 251 patients with HIV-1 infection. Study of p24 antigen and viral burden as prognosis makers. Their value at 4 years of follow-up].
    Rubio Caballero M, Rubio Rivas C, Nogués Biau A, Falguera Sacrest M, Manonelles Fernández A.
    An Med Interna; 2001 Oct 31; 18(10):517-20. PubMed ID: 11766280
    [Abstract] [Full Text] [Related]

  • 18. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J, Caelyx/Kaposi's Sarcoma Spanish Group.
    Clin Infect Dis; 2008 Aug 01; 47(3):410-7. PubMed ID: 18582203
    [Abstract] [Full Text] [Related]

  • 19. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E, De Silvestri A, Boschi A, Tinelli C.
    AIDS Rev; 2008 Aug 01; 10(4):236-44. PubMed ID: 19092979
    [Abstract] [Full Text] [Related]

  • 20. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.